Study | Patients | Survival outcomes | Drug response | Grade 3-4 AEs % | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
mOS (months) | mPFS (months) | OSR-1y | PFSR-6m | ORR | DCR | CR | PR | SD | mDOR (months) | Ongoing response | ||||
2020 | Charles [12] | Arm A (n = 228) | 10.8 (9.2-12.9) | 4.5 (4.3-5.4) | 45.10% | 34.20% | 70.60% | 88.20% | 1.80% | 68.90% | 17.50% | 4.2 (1.0-26.0) | NR | 76.70% |
Arm B (n = 225) | 9.7 (8.6-10.7) | 4.3 (4.2-4.4) | 39.60% | NR | 61.80% | 86.70% | 0.90% | 60.90% | 24.90% | 3.7 (1.4-25.8) | 19.30% | 74.90% | ||
2017 | Ott [13] | 24 | 9.7 (4.1-NR) | 1.9 (1.7-5.9) | 37.70% | 29.20% | 33.30% | 37.60% | 4.20% | 29.20% | 4.20% | 19.4 (3.6-20.0) | 8.30% | 8.30% |
2018 | Shirish [14] | 45 | 9.6 (7.0-12.0) | 1.4 (1.3-2.8) | 37.00% | 20.00% | 11.10% | NR | 2.20% | 8.90% | NR | 10.8 (5.8-NR) | NR | 8.90% |
2019 | Kim [15] | 26 | 9.1 (6.5–15.0) | 5.0 (2.7–6.7) | 40.70% | 34.60% | 23.10% | 80.80% | 3.90% | 19.20% | 57.70% | 9.1 (3.6–11.6) | NR | 34.60% |
2019 | Welsh [16] | 33 | 8.4 (6.7-10.1) | 6.1 (4.1–8.1) | 29.20% | 51.50% | 13.16% | 33% | 3% | 12% | 18% | NR | NR | 6.00% |
2020 | Welsh [17] | 40 | 39.5 (8.0–71.0) | 19.7 (8.8–30.5) | 74.70% | 80% | 78.79% | 97% | 9.10% | 69.70% | 18.20% | NR | 3.30% | 15.00% |